As the clinical response to anti-IL-23/IL-17A biologics seems better than that to anti-TNF-α biologics in psoriasis, the IL-23/IL-17A axis likely plays a more crucial role than the TNF-α axis in the development of psoriasis [67,68,69,70,71]. This evidence concerns the gene TNF and psoriasis.